<?xml version="1.0" encoding="UTF-8"?>
<protein>
  <version>3.5</version>
  <creation_date>2013-01-15 18:57:35 -0700</creation_date>
  <update_date>2013-05-27 11:08:02 -0600</update_date>
  <accession>HMDBP01555</accession>
  <secondary_accessions>
    <accession>6851</accession>
    <accession>HMDBP05593</accession>
  </secondary_accessions>
  <protein_type>Unknown</protein_type>
  <synonyms>
    <synonym>CYPIA1</synonym>
    <synonym>Cytochrome P450 form 6</synonym>
    <synonym>Cytochrome P450-C</synonym>
    <synonym>Cytochrome P450-P1</synonym>
  </synonyms>
  <gene_name>CYP1A1</gene_name>
  <general_function>Involved in monooxygenase activity</general_function>
  <specific_function>Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics.
</specific_function>
  <pathways>
    <pathway>
      <name>Steroid hormone biosynthesis</name>
      <smpdb_id/>
      <kegg_map_id>map00140</kegg_map_id>
    </pathway>
    <pathway>
      <name>Tryptophan metabolism</name>
      <smpdb_id/>
      <kegg_map_id>map00380</kegg_map_id>
    </pathway>
    <pathway>
      <name>Retinol metabolism</name>
      <smpdb_id/>
      <kegg_map_id>map00830</kegg_map_id>
    </pathway>
    <pathway>
      <name>Metabolism of xenobiotics by cytochrome P450</name>
      <smpdb_id/>
      <kegg_map_id>map00980</kegg_map_id>
    </pathway>
    <pathway>
      <name>Chemical carcinogenesis</name>
      <smpdb_id/>
      <kegg_map_id>map05204</kegg_map_id>
    </pathway>
  </pathways>
  <metabolite_associations>
    <metabolite>
      <accession>HMDB03178</accession>
      <name>Heme</name>
    </metabolite>
    <metabolite>
      <accession>HMDB00221</accession>
      <name>NADPH</name>
    </metabolite>
    <metabolite>
      <accession>HMDB01892</accession>
      <name>Menadione</name>
    </metabolite>
    <metabolite>
      <accession>HMDB00145</accession>
      <name>Estrone</name>
    </metabolite>
    <metabolite>
      <accession>HMDB12242</accession>
      <name>Ketoconazole</name>
    </metabolite>
    <metabolite>
      <accession>HMDB01389</accession>
      <name>Melatonin</name>
    </metabolite>
    <metabolite>
      <accession>HMDB12794</accession>
      <name>4-Oxoretinal</name>
    </metabolite>
    <metabolite>
      <accession>HMDB12788</accession>
      <name>4-OH-Retinal</name>
    </metabolite>
    <metabolite>
      <accession>HMDB00876</accession>
      <name>Vitamin D3</name>
    </metabolite>
    <metabolite>
      <accession>HMDB14322</accession>
      <name>Fluvoxamine</name>
    </metabolite>
    <metabolite>
      <accession>HMDB01934</accession>
      <name>L(-)-Nicotine pestanal</name>
    </metabolite>
    <metabolite>
      <accession>HMDB14334</accession>
      <name>Bortezomib</name>
    </metabolite>
    <metabolite>
      <accession>HMDB01847</accession>
      <name>Caffeine</name>
    </metabolite>
    <metabolite>
      <accession>HMDB13921</accession>
      <name>7-Hydroxyticlopidine</name>
    </metabolite>
    <metabolite>
      <accession>HMDB01889</accession>
      <name>Theophylline</name>
    </metabolite>
    <metabolite>
      <accession>HMDB14470</accession>
      <name>Nitroprusside</name>
    </metabolite>
    <metabolite>
      <accession>HMDB14010</accession>
      <name>5-Hydroxyomeprazole</name>
    </metabolite>
    <metabolite>
      <accession>HMDB14500</accession>
      <name>Chlorzoxazone</name>
    </metabolite>
    <metabolite>
      <accession>HMDB01830</accession>
      <name>Progesterone</name>
    </metabolite>
    <metabolite>
      <accession>HMDB14008</accession>
      <name>Hydroxylansoprazole</name>
    </metabolite>
    <metabolite>
      <accession>HMDB14600</accession>
      <name>Prazosin</name>
    </metabolite>
    <metabolite>
      <accession>HMDB14609</accession>
      <name>Picrotoxin</name>
    </metabolite>
    <metabolite>
      <accession>HMDB14611</accession>
      <name>Quinine</name>
    </metabolite>
    <metabolite>
      <accession>HMDB14613</accession>
      <name>Dronabinol</name>
    </metabolite>
    <metabolite>
      <accession>HMDB14642</accession>
      <name>Flutamide</name>
    </metabolite>
    <metabolite>
      <accession>HMDB14645</accession>
      <name>Haloperidol</name>
    </metabolite>
    <metabolite>
      <accession>HMDB14659</accession>
      <name>Albendazole</name>
    </metabolite>
    <metabolite>
      <accession>HMDB14667</accession>
      <name>Oxaliplatin</name>
    </metabolite>
    <metabolite>
      <accession>HMDB14671</accession>
      <name>Erlotinib</name>
    </metabolite>
    <metabolite>
      <accession>HMDB14679</accession>
      <name>Toremifene</name>
    </metabolite>
    <metabolite>
      <accession>HMDB14693</accession>
      <name>Methoxsalen</name>
    </metabolite>
    <metabolite>
      <accession>HMDB14708</accession>
      <name>Cinnarizine</name>
    </metabolite>
    <metabolite>
      <accession>HMDB13974</accession>
      <name>4'-Hydroxydiclofenac</name>
    </metabolite>
    <metabolite>
      <accession>HMDB14743</accession>
      <name>Sulindac</name>
    </metabolite>
    <metabolite>
      <accession>HMDB14746</accession>
      <name>Chloroquine</name>
    </metabolite>
    <metabolite>
      <accession>HMDB14751</accession>
      <name>Amodiaquine</name>
    </metabolite>
    <metabolite>
      <accession>HMDB00234</accession>
      <name>Testosterone</name>
    </metabolite>
    <metabolite>
      <accession>HMDB14771</accession>
      <name>Dexmedetomidine</name>
    </metabolite>
    <metabolite>
      <accession>HMDB14774</accession>
      <name>Clofibrate</name>
    </metabolite>
    <metabolite>
      <accession>HMDB14781</accession>
      <name>Mebendazole</name>
    </metabolite>
    <metabolite>
      <accession>HMDB13866</accession>
      <name>N-Desmethyltamoxifen</name>
    </metabolite>
    <metabolite>
      <accession>HMDB13880</accession>
      <name>S-6-Hydroxywarfarin</name>
    </metabolite>
    <metabolite>
      <accession>HMDB14831</accession>
      <name>Fluorescein</name>
    </metabolite>
    <metabolite>
      <accession>HMDB14832</accession>
      <name>Daunorubicin</name>
    </metabolite>
    <metabolite>
      <accession>HMDB14868</accession>
      <name>Thiabendazole</name>
    </metabolite>
    <metabolite>
      <accession>HMDB14876</accession>
      <name>Pentamidine</name>
    </metabolite>
    <metabolite>
      <accession>HMDB14878</accession>
      <name>Riluzole</name>
    </metabolite>
    <metabolite>
      <accession>HMDB00151</accession>
      <name>Estradiol</name>
    </metabolite>
    <metabolite>
      <accession>HMDB14942</accession>
      <name>Dicyclomine</name>
    </metabolite>
    <metabolite>
      <accession>HMDB14018</accession>
      <name>4-Hydroxypropofol</name>
    </metabolite>
    <metabolite>
      <accession>HMDB14989</accession>
      <name>Dacarbazine</name>
    </metabolite>
    <metabolite>
      <accession>HMDB15020</accession>
      <name>Clomifene</name>
    </metabolite>
    <metabolite>
      <accession>HMDB15026</accession>
      <name>Granisetron</name>
    </metabolite>
    <metabolite>
      <accession>HMDB00108</accession>
      <name>Ethanol</name>
    </metabolite>
    <metabolite>
      <accession>HMDB15044</accession>
      <name>Quinidine</name>
    </metabolite>
    <metabolite>
      <accession>HMDB15148</accession>
      <name>Clobetasol</name>
    </metabolite>
    <metabolite>
      <accession>HMDB13870</accession>
      <name>cis,trans-5'-Hydroxythalidomide</name>
    </metabolite>
    <metabolite>
      <accession>HMDB15192</accession>
      <name>Norfloxacin</name>
    </metabolite>
    <metabolite>
      <accession>HMDB15197</accession>
      <name>Isoproterenol</name>
    </metabolite>
    <metabolite>
      <accession>HMDB15219</accession>
      <name>Primaquine</name>
    </metabolite>
    <metabolite>
      <accession>HMDB15224</accession>
      <name>Ouabain</name>
    </metabolite>
    <metabolite>
      <accession>HMDB14037</accession>
      <name>6-Hydroxyfluvastatin</name>
    </metabolite>
    <metabolite>
      <accession>HMDB15247</accession>
      <name>Nifedipine</name>
    </metabolite>
    <metabolite>
      <accession>HMDB13946</accession>
      <name>8-Hydroxycarvedilol</name>
    </metabolite>
    <metabolite>
      <accession>HMDB15298</accession>
      <name>Itraconazole</name>
    </metabolite>
    <metabolite>
      <accession>HMDB15300</accession>
      <name>Arsenic trioxide</name>
    </metabolite>
    <metabolite>
      <accession>HMDB15364</accession>
      <name>Dexamethasone</name>
    </metabolite>
    <metabolite>
      <accession>HMDB15384</accession>
      <name>Dasatinib</name>
    </metabolite>
    <metabolite>
      <accession>HMDB15465</accession>
      <name>Bezafibrate</name>
    </metabolite>
    <metabolite>
      <accession>HMDB15477</accession>
      <name>Clenbuterol</name>
    </metabolite>
    <metabolite>
      <accession>HMDB15589</accession>
      <name>Flunarizine</name>
    </metabolite>
    <metabolite>
      <accession>HMDB01377</accession>
      <name>Oxygen</name>
    </metabolite>
    <metabolite>
      <accession>HMDB02111</accession>
      <name>Water</name>
    </metabolite>
  </metabolite_associations>
  <go_classifications>
    <go_class>
      <category>function</category>
      <description>oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygen</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>function</category>
      <description>heme binding</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>function</category>
      <description>electron carrier activity</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>function</category>
      <description>binding</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>function</category>
      <description>ion binding</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>function</category>
      <description>cation binding</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>function</category>
      <description>metal ion binding</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>function</category>
      <description>transition metal ion binding</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>function</category>
      <description>iron ion binding</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>function</category>
      <description>catalytic activity</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>function</category>
      <description>oxidoreductase activity</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>function</category>
      <description>monooxygenase activity</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>process</category>
      <description>metabolic process</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>process</category>
      <description>oxidation reduction</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>Cellular component</category>
      <description>endoplasmic reticulum membrane</description>
      <go_id>GO:0005789</go_id>
    </go_class>
    <go_class>
      <category>Cellular component</category>
      <description>mitochondrion</description>
      <go_id>GO:0005739</go_id>
    </go_class>
    <go_class>
      <category>Molecular function</category>
      <description>aromatase activity</description>
      <go_id>GO:0070330</go_id>
    </go_class>
    <go_class>
      <category>Molecular function</category>
      <description>demethylase activity</description>
      <go_id>GO:0032451</go_id>
    </go_class>
    <go_class>
      <category>Molecular function</category>
      <description>electron carrier activity</description>
      <go_id>GO:0009055</go_id>
    </go_class>
    <go_class>
      <category>Molecular function</category>
      <description>flavonoid 3'-monooxygenase activity</description>
      <go_id>GO:0016711</go_id>
    </go_class>
    <go_class>
      <category>Molecular function</category>
      <description>heme binding</description>
      <go_id>GO:0020037</go_id>
    </go_class>
    <go_class>
      <category>Molecular function</category>
      <description>iron ion binding</description>
      <go_id>GO:0005506</go_id>
    </go_class>
    <go_class>
      <category>Molecular function</category>
      <description>oxidoreductase activity, acting on diphenols and related substances as donors</description>
      <go_id>GO:0016679</go_id>
    </go_class>
    <go_class>
      <category>Molecular function</category>
      <description>oxygen binding</description>
      <go_id>GO:0019825</go_id>
    </go_class>
    <go_class>
      <category>Molecular function</category>
      <description>steroid hydroxylase activity</description>
      <go_id>GO:0008395</go_id>
    </go_class>
    <go_class>
      <category>Molecular function</category>
      <description>vitamin D 24-hydroxylase activity</description>
      <go_id>GO:0070576</go_id>
    </go_class>
    <go_class>
      <category>Biological process</category>
      <description>9-cis-retinoic acid biosynthetic process</description>
      <go_id>GO:0042904</go_id>
    </go_class>
    <go_class>
      <category>Biological process</category>
      <description>amine metabolic process</description>
      <go_id>GO:0009308</go_id>
    </go_class>
    <go_class>
      <category>Biological process</category>
      <description>camera-type eye development</description>
      <go_id>GO:0043010</go_id>
    </go_class>
    <go_class>
      <category>Biological process</category>
      <description>cell proliferation</description>
      <go_id>GO:0008283</go_id>
    </go_class>
    <go_class>
      <category>Biological process</category>
      <description>cellular lipid metabolic process</description>
      <go_id>GO:0044255</go_id>
    </go_class>
    <go_class>
      <category>Biological process</category>
      <description>coumarin metabolic process</description>
      <go_id>GO:0009804</go_id>
    </go_class>
    <go_class>
      <category>Biological process</category>
      <description>dibenzo-p-dioxin catabolic process</description>
      <go_id>GO:0019341</go_id>
    </go_class>
    <go_class>
      <category>Biological process</category>
      <description>digestive tract development</description>
      <go_id>GO:0048565</go_id>
    </go_class>
    <go_class>
      <category>Biological process</category>
      <description>drug metabolic process</description>
      <go_id>GO:0017144</go_id>
    </go_class>
    <go_class>
      <category>Biological process</category>
      <description>embryo development ending in birth or egg hatching</description>
      <go_id>GO:0009792</go_id>
    </go_class>
    <go_class>
      <category>Biological process</category>
      <description>flavonoid metabolic process</description>
      <go_id>GO:0009812</go_id>
    </go_class>
    <go_class>
      <category>Biological process</category>
      <description>hepatocyte differentiation</description>
      <go_id>GO:0070365</go_id>
    </go_class>
    <go_class>
      <category>Biological process</category>
      <description>hydrogen peroxide biosynthetic process</description>
      <go_id>GO:0050665</go_id>
    </go_class>
    <go_class>
      <category>Biological process</category>
      <description>insecticide metabolic process</description>
      <go_id>GO:0017143</go_id>
    </go_class>
    <go_class>
      <category>Biological process</category>
      <description>maternal process involved in parturition</description>
      <go_id>GO:0060137</go_id>
    </go_class>
    <go_class>
      <category>Biological process</category>
      <description>porphyrin-containing compound metabolic process</description>
      <go_id>GO:0006778</go_id>
    </go_class>
    <go_class>
      <category>Biological process</category>
      <description>positive regulation of S phase of mitotic cell cycle</description>
      <go_id>GO:0045750</go_id>
    </go_class>
    <go_class>
      <category>Biological process</category>
      <description>response to antibiotic</description>
      <go_id>GO:0046677</go_id>
    </go_class>
    <go_class>
      <category>Biological process</category>
      <description>response to arsenic-containing substance</description>
      <go_id>GO:0046685</go_id>
    </go_class>
    <go_class>
      <category>Biological process</category>
      <description>response to drug</description>
      <go_id>GO:0042493</go_id>
    </go_class>
    <go_class>
      <category>Biological process</category>
      <description>response to food</description>
      <go_id>GO:0032094</go_id>
    </go_class>
    <go_class>
      <category>Biological process</category>
      <description>response to herbicide</description>
      <go_id>GO:0009635</go_id>
    </go_class>
    <go_class>
      <category>Biological process</category>
      <description>response to hyperoxia</description>
      <go_id>GO:0055093</go_id>
    </go_class>
    <go_class>
      <category>Biological process</category>
      <description>response to hypoxia</description>
      <go_id>GO:0001666</go_id>
    </go_class>
    <go_class>
      <category>Biological process</category>
      <description>response to iron(III) ion</description>
      <go_id>GO:0010041</go_id>
    </go_class>
    <go_class>
      <category>Biological process</category>
      <description>response to lipopolysaccharide</description>
      <go_id>GO:0032496</go_id>
    </go_class>
    <go_class>
      <category>Biological process</category>
      <description>response to nematode</description>
      <go_id>GO:0009624</go_id>
    </go_class>
    <go_class>
      <category>Biological process</category>
      <description>response to organic cyclic compound</description>
      <go_id>GO:0014070</go_id>
    </go_class>
    <go_class>
      <category>Biological process</category>
      <description>response to virus</description>
      <go_id>GO:0009615</go_id>
    </go_class>
    <go_class>
      <category>Biological process</category>
      <description>response to vitamin A</description>
      <go_id>GO:0033189</go_id>
    </go_class>
    <go_class>
      <category>Biological process</category>
      <description>response to wounding</description>
      <go_id>GO:0009611</go_id>
    </go_class>
    <go_class>
      <category>Biological process</category>
      <description>vitamin D metabolic process</description>
      <go_id>GO:0042359</go_id>
    </go_class>
    <go_class>
      <category>Biological process</category>
      <description>xenobiotic metabolic process</description>
      <go_id>GO:0006805</go_id>
    </go_class>
  </go_classifications>
  <subcellular_locations>
    <subcellular_location>Endoplasmic reticulum membrane</subcellular_location>
    <subcellular_location>Peripheral membrane protein</subcellular_location>
    <subcellular_location>Microsome membrane</subcellular_location>
    <subcellular_location>Peripheral membrane protein</subcellular_location>
  </subcellular_locations>
  <gene_properties>
    <chromosome_location>15</chromosome_location>
    <locus>15q24.1</locus>
    <gene_sequence>&gt;1539 bp
ATGCTTTTCCCAATCTCCATGTCGGCCACGGAGTTTCTTCTGGCCTCTGTCATCTTCTGT
CTGGTATTCTGGGTAATGAGGGCCTCAAGACCTCAGGTCCCCAAAGGCCTGAAGAATCCA
CCAGGGCCATGGGGCTGGCCTCTGATTGGGCACATGCTGACCCTGGGAAAGAACCCGCAC
CTGGCACTGTCAAGGATGAGCCAGCAGTATGGGGACGTGCTGCAGATCCGAATTGGCTCC
ACACCCGTGGTGGTGCTGAGCGGCCTGGACACCATCCGGCAGGCCCTGGTGCGGCAGGGC
GATGATTTCAAGGGCCGGCCCGACCTCTACACCTTCACCCTCATCAGTAATGGTCAGAGC
ATGTCCTTCAGCCCAGACTCTGGACCAGTGTGGGCTGCCCGCCGGCGCCTGGCCCAGAAT
GGCCTGAAAAGTTTCTCCATTGCCTCTGACCCAGCCTCCTCAACCTCCTGCTACCTGGAA
GAGCATGTGAGCAAGGAGGCTGAGGTCCTGATAAGCACGTTGCAGGAGCTGATGGCAGGG
CCTGGGCACTTTAACCCCTACAGGTATGTGGTGGTATCAGTGACCAATGTCATCTGTGCC
ATTTGCTTTGGCCGGCGCTATGACCACAACCACCAAGAACTGCTTAGCCTAGTCAACCTG
AATAATAATTTCGGGGAGGTGGTTGGCTCTGGAAACCCAGCTGAGTTCATCCCTATTCTT
CGCTACCTACCCAACCCTTCCCTGAATGCCTTCAAGGACCTGAATGAGAAGTTCTACAGC
TTCATGCAGAAGATGGTCAAGGAGCACTACAAAACCTTTGAGAAGGGCCACATCCGGGAC
ATCACAGACAGCCTGATTGAGCACTGTCAGGAGAAGCAGCTGGATGAGAACGCCAATGTC
CAGCTGTCAGATGAGAAGATCATTAACATCGTCTTGGACCTCTTTGGAGCTGGGTTTGAC
ACAGTCACAACTGCTATCTCCTGGAGCCTCATGTATTTGGTGATGAACCCCAGGGTACAG
AGAAAGATCCAAGAGGAGCTAGACACAGTGATTGGCAGGTCACGGCGGCCCCGGCTCTCT
GACAGATCCCATCTGCCCTATATGGAGGCCTTCATCCTGGAGACCTTCCGACACTCTTCC
TTCGTCCCCTTCACCATCCCCCACAGCACAACAAGAGACACAAGTTTGAAAGGCTTTTAC
ATCCCCAAGGGGCGTTGTGTCTTTGTAAACCAGTGGCAGATCAACCATGACCAGAAGCTA
TGGGTCAACCCATCTGAGTTCCTACCTGAACGGTTTCTCACCCCTGATGGTGCTATCGAC
AAGGTGTTAAGTGAGAAGGTGATTATCTTTGGCATGGGCAAGCGGAAGTGTATCGGTGAG
ACCGTTGCCCGCTGGGAGGTCTTTCTCTTCCTGGCTATCCTGCTGCAACGGGTGGAATTC
AGCGTGCCACTGGGCGTGAAGGTGGACATGACCCCCATCTATGGGCTAACCATGAAGCAT
GCCTGCTGTGAGCACTTCCAAATGCAGCTGCGCTCTTAG</gene_sequence>
  </gene_properties>
  <protein_properties>
    <residue_number>512</residue_number>
    <molecular_weight>58164.815</molecular_weight>
    <theoretical_pi>8.347</theoretical_pi>
    <pfams>
      <pfam>
        <name>p450</name>
        <pfam_id>PF00067</pfam_id>
      </pfam>
    </pfams>
    <transmembrane_regions>
    </transmembrane_regions>
    <signal_regions>
    </signal_regions>
    <protein_sequence>&gt;Cytochrome P450 1A1
MLFPISMSATEFLLASVIFCLVFWVIRASRPQVPKGLKNPPGPWGWPLIGHMLTLGKNPH
LALSRMSQQYGDVLQIRIGSTPVVVLSGLDTIRQALVRQGDDFKGRPDLYTFTLISNGQS
MSFSPDSGPVWAARRRLAQNGLKSFSIASDPASSTSCYLEEHVSKEAEVLISTLQELMAG
PGHFNPYRYVVVSVTNVICAICFGRRYDHNHQELLSLVNLNNNFGEVVGSGNPADFIPIL
RYLPNPSLNAFKDLNEKFYSFMQKMVKEHYKTFEKGHIRDITDSLIEHCQEKQLDENANV
QLSDEKIINIVLDLFGAGFDTVTTAISWSLMYLVMNPRVQRKIQEELDTVIGRSRRPRLS
DRSHLPYMEAFILETFRHSSFVPFTIPHSTTRDTSLKGFYIPKGRCVFVNQWQINHDQKL
WVNPSEFLPERFLTPDGAIDKVLSEKVIIFGMGKRKCIGETIARWEVFLFLAILLQRVEF
SVPLGVKVDMTPIYGLTMKHACCEHFQMQLRS</protein_sequence>
  </protein_properties>
  <genbank_protein_id>181276</genbank_protein_id>
  <uniprot_id>P04798</uniprot_id>
  <uniprot_name>CP1A1_HUMAN</uniprot_name>
  <pdb_ids>
  </pdb_ids>
  <genbank_gene_id>K03191</genbank_gene_id>
  <genecard_id>CYP1A1</genecard_id>
  <geneatlas_id>CYP1A1</geneatlas_id>
  <hgnc_id>HGNC:2595</hgnc_id>
  <general_references>
    <reference>
      <reference_text>Jaiswal AK, Gonzalez FJ, Nebert DW: Human P1-450 gene sequence and correlation of mRNA with genetic differences in benzo[a]pyrene metabolism. Nucleic Acids Res. 1985 Jun 25;13(12):4503-20.</reference_text>
      <pubmed_id>2989797</pubmed_id>
    </reference>
    <reference>
      <reference_text>Jaiswal AK, Gonzalez FJ, Nebert DW: Human dioxin-inducible cytochrome P1-450: complementary DNA and amino acid sequence. Science. 1985 Apr 5;228(4695):80-3.</reference_text>
      <pubmed_id>3838385</pubmed_id>
    </reference>
    <reference>
      <reference_text>Kawajiri K, Watanabe J, Gotoh O, Tagashira Y, Sogawa K, Fujii-Kuriyama Y: Structure and drug inducibility of the human cytochrome P-450c gene.  Eur J Biochem. 1986 Sep 1;159(2):219-25.</reference_text>
      <pubmed_id>3019683</pubmed_id>
    </reference>
    <reference>
      <reference_text>Corchero J, Pimprale S, Kimura S, Gonzalez FJ: Organization of the CYP1A cluster on human chromosome 15: implications for gene regulation. Pharmacogenetics. 2001 Feb;11(1):1-6.</reference_text>
      <pubmed_id>11207026</pubmed_id>
    </reference>
    <reference>
      <reference_text>Gerhard DS, Wagner L, Feingold EA, Shenmen CM, Grouse LH, Schuler G, Klein SL, Old S, Rasooly R, Good P, Guyer M, Peck AM, Derge JG, Lipman D, Collins FS, Jang W, Sherry S, Feolo M, Misquitta L, Lee E, Rotmistrovsky K, Greenhut SF, Schaefer CF, Buetow K, Bonner TI, Haussler D, Kent J, Kiekhaus M, Furey T, Brent M, Prange C, Schreiber K, Shapiro N, Bhat NK, Hopkins RF, Hsie F, Driscoll T, Soares MB, Casavant TL, Scheetz TE, Brown-stein MJ, Usdin TB, Toshiyuki S, Carninci P, Piao Y, Dudekula DB, Ko MS, Kawakami K, Suzuki Y, Sugano S, Gruber CE, Smith MR, Simmons B, Moore T, Waterman R, Johnson SL, Ruan Y, Wei CL, Mathavan S, Gunaratne PH, Wu J, Garcia AM, Hulyk SW, Fuh E, Yuan Y, Sneed A, Kowis C, Hodgson A, Muzny DM, McPherson J, Gibbs RA, Fahey J, Helton E, Ketteman M, Madan A, Rodrigues S, Sanchez A, Whiting M, Madari A, Young AC, Wetherby KD, Granite SJ, Kwong PN, Brinkley CP, Pearson RL, Bouffard GG, Blakesly RW, Green ED, Dickson MC, Rodriguez AC, Grimwood J, Schmutz J, Myers RM, Butterfield YS, Griffith M, Griffith OL, Krzywinski MI, Liao N, Morin R, Palmquist D, Petrescu AS, Skalska U, Smailus DE, Stott JM, Schnerch A, Schein JE, Jones SJ, Holt RA, Baross A, Marra MA, Clifton S, Makowski KA, Bosak S, Malek J: The status, quality, and expansion of the NIH full-length cDNA project: the Mammalian Gene Collection (MGC). Genome Res. 2004 Oct;14(10B):2121-7.</reference_text>
      <pubmed_id>15489334</pubmed_id>
    </reference>
    <reference>
      <reference_text>Yun CH, Park HJ, Kim SJ, Kim HK: Identification of cytochrome P450 1A1 in human brain.  Biochem Biophys Res Commun. 1998 Feb 24;243(3):808-10.</reference_text>
      <pubmed_id>9500998</pubmed_id>
    </reference>
    <reference>
      <reference_text>Quattrochi LC, Okino ST, Pendurthi UR, Tukey RH: Cloning and isolation of human cytochrome P-450 cDNAs homologous to dioxin-inducible rabbit mRNAs encoding P-450 4 and P-450 6. DNA. 1985 Oct;4(5):395-400.</reference_text>
      <pubmed_id>3000715</pubmed_id>
    </reference>
    <reference>
      <reference_text>Olsen JV, Blagoev B, Gnad F, Macek B, Kumar C, Mortensen P, Mann M: Global, in vivo, and site-specific phosphorylation dynamics in signaling networks. Cell. 2006 Nov 3;127(3):635-48.</reference_text>
      <pubmed_id>17081983</pubmed_id>
    </reference>
    <reference>
      <reference_text>Hayashi S, Watanabe J, Nakachi K, Kawajiri K: Genetic linkage of lung cancer-associated MspI polymorphisms with amino acid replacement in the heme binding region of the human cytochrome P450IA1 gene. J Biochem (Tokyo). 1991 Sep;110(3):407-11.</reference_text>
      <pubmed_id>1722803</pubmed_id>
    </reference>
    <reference>
      <reference_text>Cascorbi I, Brockmoller J, Roots I: A C4887A polymorphism in exon 7 of human CYP1A1: population frequency, mutation linkages, and impact on lung cancer susceptibility. Cancer Res. 1996 Nov 1;56(21):4965-9.</reference_text>
      <pubmed_id>8895751</pubmed_id>
    </reference>
    <reference>
      <reference_text>Smart J, Daly AK: Variation in induced CYP1A1 levels: relationship to CYP1A1, Ah receptor and GSTM1 polymorphisms. Pharmacogenetics. 2000 Feb;10(1):11-24.</reference_text>
      <pubmed_id>10739168</pubmed_id>
    </reference>
    <reference>
      <reference_text>Chevalier D, Allorge D, Lo-Guidice JM, Cauffiez C, Lhermitte M, Lafitte JJ, Broly F: Detection of known and two novel (M331I and R464S) missense mutations in the human CYP1A1 gene in a French Caucasian population. Hum Mutat. 2001 Apr;17(4):355.</reference_text>
      <pubmed_id>11295847</pubmed_id>
    </reference>
    <reference>
      <reference_text>Saito T, Egashira M, Kiyotani K, Fujieda M, Yamazaki H, Kiyohara C, Kunitoh H, Kamataki T: Novel nonsynonymous polymorphisms of the CYP1A1 gene in Japanese.  Drug Metab Pharmacokinet. 2003;18(3):218-21.</reference_text>
      <pubmed_id>15618738</pubmed_id>
    </reference>
    <reference>
      <reference_text>Solus JF, Arietta BJ, Harris JR, Sexton DP, Steward JQ, McMunn C, Ihrie P, Mehall JM, Edwards TL, Dawson EP: Genetic variation in eleven phase I drug metabolism genes in an ethnically diverse population. Pharmacogenomics. 2004 Oct;5(7):895-931.</reference_text>
      <pubmed_id>15469410</pubmed_id>
    </reference>
    <reference>
      <reference_text>Jiang Z, Dalton TP, Jin L, Wang B, Tsuneoka Y, Shertzer HG, Deka R, Nebert DW: Toward the evaluation of function in genetic variability: characterizing human SNP frequencies and establishing BAC-transgenic mice carrying the human CYP1A1_CYP1A2 locus. Hum Mutat. 2005 Feb;25(2):196-206.</reference_text>
      <pubmed_id>15643613</pubmed_id>
    </reference>
    <reference>
      <reference_text>Sjoblom T, Jones S, Wood LD, Parsons DW, Lin J, Barber TD, Mandelker D, Leary RJ, Ptak J, Silliman N, Szabo S, Buckhaults P, Farrell C, Meeh P, Markowitz SD, Willis J, Dawson D, Willson JK, Gazdar AF, Hartigan J, Wu L, Liu C, Parmigiani G, Park BH, Bachman KE, Papadopoulos N, Vogelstein B, Kinzler KW, Velculescu VE: The consensus coding sequences of human breast and colorectal cancers.  Science. 2006 Oct 13;314(5797):268-74. Epub 2006 Sep 7.</reference_text>
      <pubmed_id>16959974</pubmed_id>
    </reference>
  </general_references>
  <metabolite_references>
    <metabolite_reference>
      <metabolite>
        <name>Menadione</name>
        <accession>HMDB01892</accession>
      </metabolite>
      <reference>
        <reference_text>Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. Epub 2009 Nov 24.</reference_text>
        <pubmed_id>19934256</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Melatonin</name>
        <accession>HMDB01389</accession>
      </metabolite>
      <reference>
        <reference_text>Chang TK, Chen J, Yang G, Yeung EY: Inhibition of procarcinogen-bioactivating human CYP1A1, CYP1A2 and CYP1B1 enzymes by melatonin. J Pineal Res. 2010 Jan;48(1):55-64. Epub 2009 Nov 16.</reference_text>
        <pubmed_id>19919601</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Melatonin</name>
        <accession>HMDB01389</accession>
      </metabolite>
      <reference>
        <reference_text>Ma X, Idle JR, Krausz KW, Gonzalez FJ: Metabolism of melatonin by human cytochromes p450.  Drug Metab Dispos. 2005 Apr;33(4):489-94. Epub 2004 Dec 22.</reference_text>
        <pubmed_id>15616152</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Melatonin</name>
        <accession>HMDB01389</accession>
      </metabolite>
      <reference>
        <reference_text>Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. Epub 2009 Nov 24.</reference_text>
        <pubmed_id>19934256</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Vitamin D3</name>
        <accession>HMDB00876</accession>
      </metabolite>
      <reference>
        <reference_text>Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. Epub 2009 Nov 24.</reference_text>
        <pubmed_id>19934256</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Fluvoxamine</name>
        <accession>HMDB14322</accession>
      </metabolite>
      <reference>
        <reference_text>Baumann P: Pharmacokinetic-pharmacodynamic relationship of the selective serotonin reuptake inhibitors. Clin Pharmacokinet. 1996 Dec;31(6):444-69.</reference_text>
        <pubmed_id>8968657</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Fluvoxamine</name>
        <accession>HMDB14322</accession>
      </metabolite>
      <reference>
        <reference_text>Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. Epub 2009 Nov 24.</reference_text>
        <pubmed_id>19934256</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>L(-)-Nicotine pestanal</name>
        <accession>HMDB01934</accession>
      </metabolite>
      <reference>
        <reference_text>Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. Epub 2009 Nov 24.</reference_text>
        <pubmed_id>19934256</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Bortezomib</name>
        <accession>HMDB14334</accession>
      </metabolite>
      <reference>
        <reference_text>Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. Epub 2009 Nov 24.</reference_text>
        <pubmed_id>19934256</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Caffeine</name>
        <accession>HMDB01847</accession>
      </metabolite>
      <reference>
        <reference_text>Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. Epub 2009 Nov 24.</reference_text>
        <pubmed_id>19934256</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>7-Hydroxyticlopidine</name>
        <accession>HMDB13921</accession>
      </metabolite>
      <reference>
        <reference_text>Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. Epub 2009 Nov 24.</reference_text>
        <pubmed_id>19934256</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Theophylline</name>
        <accession>HMDB01889</accession>
      </metabolite>
      <reference>
        <reference_text>Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. Epub 2009 Nov 24.</reference_text>
        <pubmed_id>19934256</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Nitroprusside</name>
        <accession>HMDB14470</accession>
      </metabolite>
      <reference>
        <reference_text>Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. Epub 2009 Nov 24.</reference_text>
        <pubmed_id>19934256</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>5-Hydroxyomeprazole</name>
        <accession>HMDB14010</accession>
      </metabolite>
      <reference>
        <reference_text>Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. Epub 2009 Nov 24.</reference_text>
        <pubmed_id>19934256</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Chlorzoxazone</name>
        <accession>HMDB14500</accession>
      </metabolite>
      <reference>
        <reference_text>Wiercinska P, Squires EJ: Chlorzoxazone metabolism by porcine cytochrome P450 enzymes and the effect of cytochrome b5. Drug Metab Dispos. 2010 May;38(5):857-62. Epub 2010 Feb 17.</reference_text>
        <pubmed_id>20164110</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Chlorzoxazone</name>
        <accession>HMDB14500</accession>
      </metabolite>
      <reference>
        <reference_text>Warrington JS, Court MH, Greenblatt DJ, von Moltke LL: Phenacetin and chlorzoxazone biotransformation in aging male Fischer 344 rats.  J Pharm Pharmacol. 2004 Jun;56(6):819-25.</reference_text>
        <pubmed_id>15231049</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Progesterone</name>
        <accession>HMDB01830</accession>
      </metabolite>
      <reference>
        <reference_text>Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. Epub 2009 Nov 24.</reference_text>
        <pubmed_id>19934256</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Hydroxylansoprazole</name>
        <accession>HMDB14008</accession>
      </metabolite>
      <reference>
        <reference_text>Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. Epub 2009 Nov 24.</reference_text>
        <pubmed_id>19934256</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Prazosin</name>
        <accession>HMDB14600</accession>
      </metabolite>
      <reference>
        <reference_text>Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. Epub 2009 Nov 24.</reference_text>
        <pubmed_id>19934256</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Picrotoxin</name>
        <accession>HMDB14609</accession>
      </metabolite>
      <reference>
        <reference_text>Sadar MD, Ash R, Andersson TB: Picrotoxin is a CYP1A1 inducer in rainbow trout hepatocytes.  Biochem Biophys Res Commun. 1995 Sep 25;214(3):1060-6.</reference_text>
        <pubmed_id>7575510</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Picrotoxin</name>
        <accession>HMDB14609</accession>
      </metabolite>
      <reference>
        <reference_text>Sadar MD, Westlind A, Blomstrand F, Andersson TB: Induction of CYP1A1 by GABA receptor ligands.  Biochem Biophys Res Commun. 1996 Dec 4;229(1):231-7.</reference_text>
        <pubmed_id>8954111</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Quinine</name>
        <accession>HMDB14611</accession>
      </metabolite>
      <reference>
        <reference_text>Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. Epub 2009 Nov 24.</reference_text>
        <pubmed_id>19934256</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Dronabinol</name>
        <accession>HMDB14613</accession>
      </metabolite>
      <reference>
        <reference_text>Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. Epub 2009 Nov 24.</reference_text>
        <pubmed_id>19934256</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Flutamide</name>
        <accession>HMDB14642</accession>
      </metabolite>
      <reference>
        <reference_text>Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. Epub 2009 Nov 24.</reference_text>
        <pubmed_id>19934256</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Haloperidol</name>
        <accession>HMDB14645</accession>
      </metabolite>
      <reference>
        <reference_text>Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. Epub 2009 Nov 24.</reference_text>
        <pubmed_id>19934256</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Albendazole</name>
        <accession>HMDB14659</accession>
      </metabolite>
      <reference>
        <reference_text>Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. Epub 2009 Nov 24.</reference_text>
        <pubmed_id>19934256</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Oxaliplatin</name>
        <accession>HMDB14667</accession>
      </metabolite>
      <reference>
        <reference_text>Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. Epub 2009 Nov 24.</reference_text>
        <pubmed_id>19934256</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Erlotinib</name>
        <accession>HMDB14671</accession>
      </metabolite>
      <reference>
        <reference_text>van Erp NP, Gelderblom H, Guchelaar HJ: Clinical pharmacokinetics of tyrosine kinase inhibitors.  Cancer Treat Rev. 2009 Dec;35(8):692-706. Epub 2009 Sep 5.</reference_text>
        <pubmed_id>19733976</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Erlotinib</name>
        <accession>HMDB14671</accession>
      </metabolite>
      <reference>
        <reference_text>Johnson JR, Cohen M, Sridhara R, Chen YF, Williams GM, Duan J, Gobburu J, Booth B, Benson K, Leighton J, Hsieh LS, Chidambaram N, Zimmerman P, Pazdur R: Approval summary for erlotinib for treatment of patients with locally advanced or metastatic non-small cell lung cancer after failure of at least one prior chemotherapy regimen. Clin Cancer Res. 2005 Sep 15;11(18):6414-21.</reference_text>
        <pubmed_id>16166415</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Erlotinib</name>
        <accession>HMDB14671</accession>
      </metabolite>
      <reference>
        <reference_text>Li J, Zhao M, He P, Hidalgo M, Baker SD: Differential metabolism of gefitinib and erlotinib by human cytochrome P450 enzymes. Clin Cancer Res. 2007 Jun 15;13(12):3731-7.</reference_text>
        <pubmed_id>17575239</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Toremifene</name>
        <accession>HMDB14679</accession>
      </metabolite>
      <reference>
        <reference_text>Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. Epub 2009 Nov 24.</reference_text>
        <pubmed_id>19934256</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Methoxsalen</name>
        <accession>HMDB14693</accession>
      </metabolite>
      <reference>
        <reference_text>Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. Epub 2009 Nov 24.</reference_text>
        <pubmed_id>19934256</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Cinnarizine</name>
        <accession>HMDB14708</accession>
      </metabolite>
      <reference>
        <reference_text>Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1.</reference_text>
        <pubmed_id>19515014</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Cinnarizine</name>
        <accession>HMDB14708</accession>
      </metabolite>
      <reference>
        <reference_text>Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. Epub 2009 Nov 24.</reference_text>
        <pubmed_id>19934256</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>4'-Hydroxydiclofenac</name>
        <accession>HMDB13974</accession>
      </metabolite>
      <reference>
        <reference_text>Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. Epub 2009 Nov 24.</reference_text>
        <pubmed_id>19934256</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Sulindac</name>
        <accession>HMDB14743</accession>
      </metabolite>
      <reference>
        <reference_text>Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. Epub 2009 Nov 24.</reference_text>
        <pubmed_id>19934256</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Chloroquine</name>
        <accession>HMDB14746</accession>
      </metabolite>
      <reference>
        <reference_text>Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. Epub 2009 Nov 24.</reference_text>
        <pubmed_id>19934256</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Amodiaquine</name>
        <accession>HMDB14751</accession>
      </metabolite>
      <reference>
        <reference_text>Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. Epub 2009 Nov 24.</reference_text>
        <pubmed_id>19934256</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Testosterone</name>
        <accession>HMDB00234</accession>
      </metabolite>
      <reference>
        <reference_text>Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. Epub 2009 Nov 24.</reference_text>
        <pubmed_id>19934256</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Dexmedetomidine</name>
        <accession>HMDB14771</accession>
      </metabolite>
      <reference>
        <reference_text>Konstandi M, Kostakis D, Harkitis P, Marselos M, Johnson EO, Adamidis K, Lang MA: Role of adrenoceptor-linked signaling pathways in the regulation of CYP1A1 gene expression. Biochem Pharmacol. 2005 Jan 15;69(2):277-87.</reference_text>
        <pubmed_id>15627480</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Clofibrate</name>
        <accession>HMDB14774</accession>
      </metabolite>
      <reference>
        <reference_text>Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. Epub 2009 Nov 24.</reference_text>
        <pubmed_id>19934256</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Mebendazole</name>
        <accession>HMDB14781</accession>
      </metabolite>
      <reference>
        <reference_text>Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. Epub 2009 Nov 24.</reference_text>
        <pubmed_id>19934256</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>N-Desmethyltamoxifen</name>
        <accession>HMDB13866</accession>
      </metabolite>
      <reference>
        <reference_text>Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1.</reference_text>
        <pubmed_id>19515014</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>N-Desmethyltamoxifen</name>
        <accession>HMDB13866</accession>
      </metabolite>
      <reference>
        <reference_text>Crewe HK, Notley LM, Wunsch RM, Lennard MS, Gillam EM: Metabolism of tamoxifen by recombinant human cytochrome P450 enzymes: formation of the 4-hydroxy, 4'-hydroxy and N-desmethyl metabolites and isomerization of trans-4-hydroxytamoxifen. Drug Metab Dispos. 2002 Aug;30(8):869-74.</reference_text>
        <pubmed_id>12124303</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>N-Desmethyltamoxifen</name>
        <accession>HMDB13866</accession>
      </metabolite>
      <reference>
        <reference_text>Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. Epub 2009 Nov 24.</reference_text>
        <pubmed_id>19934256</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>S-6-Hydroxywarfarin</name>
        <accession>HMDB13880</accession>
      </metabolite>
      <reference>
        <reference_text>Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1.</reference_text>
        <pubmed_id>19515014</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Fluorescein</name>
        <accession>HMDB14831</accession>
      </metabolite>
      <reference>
        <reference_text>Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. Epub 2009 Nov 24.</reference_text>
        <pubmed_id>19934256</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Daunorubicin</name>
        <accession>HMDB14832</accession>
      </metabolite>
      <reference>
        <reference_text>Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. Epub 2009 Nov 24.</reference_text>
        <pubmed_id>19934256</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Thiabendazole</name>
        <accession>HMDB14868</accession>
      </metabolite>
      <reference>
        <reference_text>Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. Epub 2009 Nov 24.</reference_text>
        <pubmed_id>19934256</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Pentamidine</name>
        <accession>HMDB14876</accession>
      </metabolite>
      <reference>
        <reference_text>Li XQ, Bjorkman A, Andersson TB, Gustafsson LL, Masimirembwa CM: Identification of human cytochrome P(450)s that metabolise anti-parasitic drugs and predictions of in vivo drug hepatic clearance from in vitro data. Eur J Clin Pharmacol. 2003 Sep;59(5-6):429-42. Epub 2003 Aug 12.</reference_text>
        <pubmed_id>12920490</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Riluzole</name>
        <accession>HMDB14878</accession>
      </metabolite>
      <reference>
        <reference_text>Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. Epub 2009 Nov 24.</reference_text>
        <pubmed_id>19934256</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Estradiol</name>
        <accession>HMDB00151</accession>
      </metabolite>
      <reference>
        <reference_text>Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. Epub 2009 Nov 24.</reference_text>
        <pubmed_id>19934256</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Dicyclomine</name>
        <accession>HMDB14942</accession>
      </metabolite>
      <reference>
        <reference_text>Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. Epub 2009 Nov 24.</reference_text>
        <pubmed_id>19934256</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>4-Hydroxypropofol</name>
        <accession>HMDB14018</accession>
      </metabolite>
      <reference>
        <reference_text>Chen TL, Ueng TH, Chen SH, Lee PH, Fan SZ, Liu CC: Human cytochrome P450 mono-oxygenase system is suppressed by propofol.  Br J Anaesth. 1995 May;74(5):558-62.</reference_text>
        <pubmed_id>7772432</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>4-Hydroxypropofol</name>
        <accession>HMDB14018</accession>
      </metabolite>
      <reference>
        <reference_text>Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. Epub 2009 Nov 24.</reference_text>
        <pubmed_id>19934256</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Dacarbazine</name>
        <accession>HMDB14989</accession>
      </metabolite>
      <reference>
        <reference_text>Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. Epub 2009 Nov 24.</reference_text>
        <pubmed_id>19934256</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Clomifene</name>
        <accession>HMDB15020</accession>
      </metabolite>
      <reference>
        <reference_text>Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. Epub 2009 Nov 24.</reference_text>
        <pubmed_id>19934256</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Granisetron</name>
        <accession>HMDB15026</accession>
      </metabolite>
      <reference>
        <reference_text>Nakamura H, Ariyoshi N, Okada K, Nakasa H, Nakazawa K, Kitada M: CYP1A1 is a major enzyme responsible for the metabolism of granisetron in human liver microsomes. Curr Drug Metab. 2005 Oct;6(5):469-80.</reference_text>
        <pubmed_id>16248838</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Granisetron</name>
        <accession>HMDB15026</accession>
      </metabolite>
      <reference>
        <reference_text>Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. Epub 2009 Nov 24.</reference_text>
        <pubmed_id>19934256</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Ethanol</name>
        <accession>HMDB00108</accession>
      </metabolite>
      <reference>
        <reference_text>Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. Epub 2009 Nov 24.</reference_text>
        <pubmed_id>19934256</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Quinidine</name>
        <accession>HMDB15044</accession>
      </metabolite>
      <reference>
        <reference_text>Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. Epub 2009 Nov 24.</reference_text>
        <pubmed_id>19934256</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Clobetasol</name>
        <accession>HMDB15148</accession>
      </metabolite>
      <reference>
        <reference_text>Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. Epub 2009 Nov 24.</reference_text>
        <pubmed_id>19934256</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>cis,trans-5'-Hydroxythalidomide</name>
        <accession>HMDB13870</accession>
      </metabolite>
      <reference>
        <reference_text>Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1.</reference_text>
        <pubmed_id>19515014</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Norfloxacin</name>
        <accession>HMDB15192</accession>
      </metabolite>
      <reference>
        <reference_text>Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. Epub 2009 Nov 24.</reference_text>
        <pubmed_id>19934256</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Isoproterenol</name>
        <accession>HMDB15197</accession>
      </metabolite>
      <reference>
        <reference_text>Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. Epub 2009 Nov 24.</reference_text>
        <pubmed_id>19934256</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Primaquine</name>
        <accession>HMDB15219</accession>
      </metabolite>
      <reference>
        <reference_text>Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. Epub 2009 Nov 24.</reference_text>
        <pubmed_id>19934256</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Ouabain</name>
        <accession>HMDB15224</accession>
      </metabolite>
      <reference>
        <reference_text>Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. Epub 2009 Nov 24.</reference_text>
        <pubmed_id>19934256</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>6-Hydroxyfluvastatin</name>
        <accession>HMDB14037</accession>
      </metabolite>
      <reference>
        <reference_text>Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1.</reference_text>
        <pubmed_id>19515014</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>6-Hydroxyfluvastatin</name>
        <accession>HMDB14037</accession>
      </metabolite>
      <reference>
        <reference_text>Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. Epub 2009 Nov 24.</reference_text>
        <pubmed_id>19934256</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Nifedipine</name>
        <accession>HMDB15247</accession>
      </metabolite>
      <reference>
        <reference_text>Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. Epub 2009 Nov 24.</reference_text>
        <pubmed_id>19934256</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>8-Hydroxycarvedilol</name>
        <accession>HMDB13946</accession>
      </metabolite>
      <reference>
        <reference_text>Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1.</reference_text>
        <pubmed_id>19515014</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Itraconazole</name>
        <accession>HMDB15298</accession>
      </metabolite>
      <reference>
        <reference_text>Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. Epub 2009 Nov 24.</reference_text>
        <pubmed_id>19934256</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Arsenic trioxide</name>
        <accession>HMDB15300</accession>
      </metabolite>
      <reference>
        <reference_text>Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. Epub 2009 Nov 24.</reference_text>
        <pubmed_id>19934256</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Dexamethasone</name>
        <accession>HMDB15364</accession>
      </metabolite>
      <reference>
        <reference_text>Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. Epub 2009 Nov 24.</reference_text>
        <pubmed_id>19934256</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Dasatinib</name>
        <accession>HMDB15384</accession>
      </metabolite>
      <reference>
        <reference_text>van Erp NP, Gelderblom H, Guchelaar HJ: Clinical pharmacokinetics of tyrosine kinase inhibitors.  Cancer Treat Rev. 2009 Dec;35(8):692-706. Epub 2009 Sep 5.</reference_text>
        <pubmed_id>19733976</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Dasatinib</name>
        <accession>HMDB15384</accession>
      </metabolite>
      <reference>
        <reference_text>Wang L, Christopher LJ, Cui D, Li W, Iyer R, Humphreys WG, Zhang D: Identification of the human enzymes involved in the oxidative metabolism of dasatinib: an effective approach for determining metabolite formation kinetics. Drug Metab Dispos. 2008 Sep;36(9):1828-39. Epub 2008 Jun 12.</reference_text>
        <pubmed_id>18556438</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Bezafibrate</name>
        <accession>HMDB15465</accession>
      </metabolite>
      <reference>
        <reference_text>Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. Epub 2009 Nov 24.</reference_text>
        <pubmed_id>19934256</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Clenbuterol</name>
        <accession>HMDB15477</accession>
      </metabolite>
      <reference>
        <reference_text>Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. Epub 2009 Nov 24.</reference_text>
        <pubmed_id>19934256</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Flunarizine</name>
        <accession>HMDB15589</accession>
      </metabolite>
      <reference>
        <reference_text>Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1.</reference_text>
        <pubmed_id>19515014</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Flunarizine</name>
        <accession>HMDB15589</accession>
      </metabolite>
      <reference>
        <reference_text>Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. Epub 2009 Nov 24.</reference_text>
        <pubmed_id>19934256</pubmed_id>
      </reference>
    </metabolite_reference>
  </metabolite_references>
</protein>
